Two male siblings with a novel LRBA mutation presenting with different findings of IPEX syndrome

Sanem Eren Akarcan, Neslihan Edeer Karaca, Guzide Aksu, Ayca Aykut, Deniz Yilmaz Karapinar, Funda Cetin, Yesim Aydinok, Elif Azarsiz, Eleonora Gambineri, OzgurCogulu, Ezgi Ulusoy Severcan, Hudaver Alper and Necil Kutukculer

Abstract

Introduction. LPS-responsive beige-like anchor (LRBA) protein deficiency is a disease of immune dysregulation with autoimmunity affecting various systems.

Case Presentation. Two male siblings with a novel LRBA mutation had different primary findings at admission: the younger sibling had chronic early-onset diarrhoea and the elder one had autoimmune haemolytic anaemia. During long-term follow-up for IPEX phenotype, both developed hypogammaglobulinaemia, enteropathy and lung involvement. The patients partially responded to immunosuppressive therapies. A homozygous c.2496C>A, p.Cys832Ter (p.C832*) mutation in the LRBA gene causing a premature stop codon was detected. After molecular diagnosis, abatacept, as a target-specific molecule, was used with promising results.

Conclusion. LRBA deficiency is a recently defined defect, with variable presentations in different patients; a single, definitive treatment option is thus not yet available.

INTRODUCTION

The immune system has distinct and interrelated cellular and humoral components composed of many cells, signalling pathways, cytokines and receptors. There are 354 primary human immune deficiency diseases with 344 gene defects, grouped into nine different categories with respect to common phenotypes [1].

LPS-responsive beige-like anchor protein (LRBA) deficiency is a relatively newly defined molecular defect, first described in 2012, in five patients with severe, early-onset hypogammaglobulinaemia and autoimmune manifestations. Susceptibility to inflammatory bowel disease (IBD), and recurrent infections were important characteristics of these patients [2]. In a similar time frame, another investigator group found LRBA mutation in five members of a large family presenting with IBD. Autoimmune cytopenia, renal disease, recurrent infections and lymphoproliferative disease were other findings [3]. LRBA deficiency was first classified in common variable immune deficiency disorders, but as the identified cases increased and different cohorts of LRBA mutant patients were published, the spectrum of the phenotype has expanded [4–6]. LRBA deficiency is now categorized as a disease of immune dysregulation with autoimmunity [1].

LRBA is a cytosolic protein which controls cytotoxic T lymphocyte-associated protein-4 (CTLA-4) expression [7]. CTLA-4 is a protein found in endocytic vesicles and released to the cell surface of regulatory T cells (Tregs) with T cell receptor (TCR) stimulation. It is an inhibitory
molecule competing with the co-stimulatory molecule CD28 for the same ligands (CD80 and CD86) on antigen-presenting cells [8]. The amount of CTLA-4 at the cell surface is important for inhibition of self-reacting T cells after antigen recognition. LRBA binds to the cytosolic tail of CTLA-4 and blocks its transport to lysosomes for removal [7]. Both heterozygous CTLA-4 and biallelic LRBA mutations result in insufficient functional CTLA-4, abolishing CTLA-4-dependent Treg function and causing immune dysregulation and autoimmunity [9].

Herein, we present two male siblings with a novel homozygous LRBA mutation with both similar and different clinical features (Table 1), expanding the possible diagnoses until the exact molecular defect was defined. These siblings were followed for immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) or IPEX-like syndrome for several years.

**CASE REPORT**

**Patient 1**

A 3-year-old boy was admitted to inpatient clinics with complaints of persistent diarrhoea and failure to thrive. He had watery, mucous, sometimes bloody defecation 3–4 times a day since 1 year of age. He was born via vaginal delivery at week 32 of gestation with birth weight of 2200 g. He had been investigated for chronic diarrhoea in a public hospital before admission to our department. Cystic fibrosis was excluded with negative sequence analysis. He had low complement 3 (C3) and C4 values with proteinuria. Kidney biopsy revealed minimal interstitial fibrosis. He was the second child of second-degree consanguineous healthy parents with three live births. The first male child and third female child were known to be healthy at that time. His paternal uncle had died in his second decade due to IgA nephropathy and chronic renal failure.

He showed failure to thrive (weight −2.03 standard deviation score (SDS), height −1.89 SDS, under the third percentile), multiple dental caries, coarse lung sounds and a 1/6 systolic murmur on his first admission. He had iron deficiency anaemia [haemoglobin (Hb): 8.5 g dl⁻¹, mean corpuscular volume (MCV): 66 fl, iron: 16 µg dl⁻¹, total iron binding capacity (TIBC): 268 µg dl⁻¹, transferrin saturation: 5.9 %, ferritin: 7.9 g l⁻¹], hypoproteinaemia and hypoalbuminaemia (total protein: 5.8 g dl⁻¹, albumin: 2.9 g dl⁻¹). C-reactive protein was 0.7 mg dl⁻¹ (normal: <0.3 mg dl⁻¹), and erythrocyte sedimentation rate was 40 mm h⁻¹ (normal: <20 mm h⁻¹). Stool examinations for lipid, blood, parasites and viruses were negative, but *Salmonella enteritidis* grew in stool culture. Thyroid hormones were within normal limits, except a mild thyroid-stimulating hormone (TSH) elevation [TSH: 6.4 µIU ml⁻¹ (normal: 0.35–5.5)] and he had been followed for compensatory hypothyroidism before admission. He had non-nephrotic proteinuria [14 mg m⁻² h⁻¹ (normal: <4 mg m⁻² h⁻¹)]. Abdominal ultrasonography (US) was normal.

He had normal IgG and IgM levels, a complete IgA deficiency and low IgE level. C3 and C4 were under the lower limit of normal values (Table 2). Lymphocyte subgroups revealed a low percentage of B cells (CD19+ cells: 4.4 %) (Table 2). Specific antibody response for *Hemophilus influenza* was sufficient, whereas tetanus was absent. He had positive cytomegalovirus (CMV) DNA in serum (481 copies ml⁻¹ by PCR) without clinical findings. Autoantibodies (antinuclear antibody, antithyroid peroxidase, antithyroglobulin antibodies) were negative while direct Coombs test was positive.

| Table 1. Clinical findings of the two patients |
|---------------------------------------------|
| **Patient 1** | **Patient 2** |
| Current age (years) | 10 | 11 |
| Age at first symptoms (years) | Diarrhoea: 1 | Recurrent bronchiolitis: 1 |
| Age at admission (years) | 3 | 7 |
| Failure to thrive | (+) | (–) at admission |
| Recurrent respiratory infections | (+) | Developed during follow up |
| Hepatosplenomegaly | (+) | (+) |
| Lymphadenopathy | (+) | (+) |
| Lung involvement | Bronchiectasis | Lymphocytic interstitial pneumonia (pathology diagnosis) |
| Endocrinological involvement | Compensatory hypothyroidism | (–) |
| Gastrointestinal involvement | Antithyroid antibody-positive | Duodenitis, microscopic colitis |
| Kidney involvement | Chronic glomerulonephritis | Focal segmental glomerulosclerosis |
| Autoimmune cytopenias | (–) | Haemolytic anaemia |
| | | Thrombocytopenia |
| | | Neutropenia |
Endoscopic evaluation of the upper and lower gastrointestinal tract showed oesophagitis, nodularity and granulation of the duodenum, granulation and fragility of the caecum, and bleeding foci and microabscesses in the colon. Microscopy revealed intraepithelial increased eosinophilic infiltration and plasma cell infiltration in lamina propria of duodenum, irregular crypt structure, and increased eosinophilic and lymphocytic infiltration in lamina propria of colon linked to allergic/oesinophilic gastrointestinal disorder. Sulfasalazine and corticosteroids were prescribed for enteropathy.

He was discharged with preliminary diagnoses of IPEX syndrome, combined immunodeficiency and common variable immunodeficiency (CVID) with positive pathological findings of autoimmune enteropathy and nephropathy. During follow-up, enteropathy continued with decreasing IgG and increasing IgM levels suggesting immunoglobulin class switch recombination defects. CD40 molecule was positive in 98% of B cells and CD40L on T cells showed the expected increase upon activation. Regular intravenous immunoglobulin (IVIG) replacement was started.

At the age of 5 years, he was hospitalized with pneumonia. He had growth retardation (weight –2.73 SDS, under 3rd percentile; height –1.21 SDS, 3–10 percentile), submandibular, cervical, axillary lymphadenomegalies reaching 2 cm, cracks in lungs and hepatosplenomegaly (spleen 5–6 cm, liver 3 cm below the costal margin) on physical examination. He had anaemia, eosinophilia (absolute eosinophil count: 1150 mm⁻³), hypogammaglobulinaemia and hypocomplementaemia. Tuberculin skin test and IFN-γ release assays were negative. In lymphocyte subgroup counts, the percentage of B cells was even lower than before (CD19: 0.8%) (Table 2).

Chest X-ray showed bilateral extensive infiltrations. Thorax computed tomography (CT) revealed extended nodules with irregular margins and calcifications suggesting granulomatous or infectious aetiology. Hepatosplenomegaly and hypoechoic nodules in spleen, bilateral supraclavicular and axillary lymph nodes reaching 3 cm (US), and retroperitoneal, mesenteric and inguinal microlymphadenopathies (CT) suggested malignancy. Bone marrow aspiration smear and biopsy showed a myeloid leukemoid reaction, supporting an infectious aetiology and excluding haematological malignancy. Lymph node excision biopsy showed non-specific reactive hyperplasia with findings compatible with immunodeficiency, such as regressive lymphoid follicular changes and decreased plasma cells.

He had recurrent infections and multi-system organ involvement such as enteropathy (with associated findings of failure to thrive, anaemia), granulomatous lung disease, nephropathy, non-malignant lymphoproliferation and hypothyroidism. Direct Coombs test positivity supported an autoimmune component of an immunodeficiency syndrome. Additionally, his elder brother (Patient 2), who was known to be healthy on first admission of Patient 1, had been followed with autoimmune lymphoproliferative syndrome (ALPS) in the public hospital for the last year.

Quantitative oxidative burst activity was normal, excluding chronic granulomatous disease. X-linked agammaglobulinemia was unlikely, although B cell percentage was <1% because of lymphoproliferation and measurable levels of IgG and IgM. Lymphoproliferation, positive Coombs test and findings of the sibling suggested ALPS but CD4-CD8-TCR α/β [double negative (DN)] T cells were in the normal range (0.39%). Lymphoproliferation not associated with Epstein–Barr virus (EBV) and negative SH2D1A mutation ruled out X-linked lymphoproliferative syndrome. Most clinical and laboratory findings supported CVID as a diagnosis but even so, very early-onset disease and the presence of the other sibling pointed to a monogenic aetiology. Clinical phenotype of the affected two male patients strongly suggested IPEX syndrome but molecular analysis of the FOXP3 gene was negative.

Prophylaxis with antibiotics and antifungals was started for infection control. Antiviral treatment for cytomegalovirus (CMV) infection was used when necessary. In his 7-year follow-up he had numerous hospitalizations due to respiratory tract infections or findings associated with worsening enteropathy such as hypoalbuminaemia and electrolyte disturbances. Corticosteroids (doses of 0.3–0.5 mg kg⁻¹ day⁻¹) were used as immunosuppressive agents intermittently at 3–6 month intervals with a slight response. Subcutaneous immunoglobulin replacement therapy was started. He had no matched sibling donor and a matched unrelated donor search was initiated for haematopoietic stem cell transplantation (HSCT).

At the age of 9 years, he had clubbing and chronic lung findings. Chest X-ray showed bilateral extended coarse reticular changes and peribronchial thickenings (Fig. 1a). Thorax CT revealed extended and severe bronchiectasis with thickened bronchial walls, some granulomatous nodules and mosaic appearance, compatible with granulomatous lymphocytic interstitial lung disease (GLILD) (Fig. 1b). His bone age was 5 years when he was 10 years old. Growth retardation got worse (weight –4.99 SDS, height –3.28 SDS, under 3rd percentile). Vitamin D insufficiency led to hyperparathyroidism, symptomatic hypocalcaemia and severe osteoporosis requiring aggressive calcium and vitamin D replacement [Ca: 5.4 mg dl⁻¹, albumin: 2.7 g dl⁻¹, parathyroid hormone (PTH): 83.41 pg ml⁻¹, vitamin D: 11 ng ml⁻¹]. Autoantibodies to the thyroid gland (antithyroid peroxidase, antithyroglobulin antibodies) became positive on follow up but thyroid US and thyroid hormones were normal.

**Patient 2**

The 7-year-old brother of Patient 1 was hospitalized with cough and respiratory insufficiency. He had recurrent bronchiolitis starting at age 6 months. At the age of 5 years, he had been admitted to the public hospital with dark urination. He had autoimmune haemolytic anaemia (AIHA)
Table 2. Serum immunoglobulin, complement levels, lymphocyte subgroups as percentages and absolute cell numbers compared to age-related reference values (at admission and during follow-up) [25–27]

| Patient | Reference values | Age 1 | Reference values | Age 2 | Reference values | Age 3 | Reference values | Age 4 | Reference values | Age 5 | Reference values | Age 6 | Reference values | Age 7 | Reference values | Age 8 | Reference values | Age 9 | Reference values | Age 10 | Reference values |
|---------|------------------|-------|------------------|-------|------------------|-------|------------------|-------|------------------|-------|------------------|-------|------------------|-------|------------------|-------|------------------|-------|------------------|-------|------------------|
| IgG (mg dl⁻¹) | 664 | 879.9±157.2 | 228 | 986.2±209.6 | 292 | 1062.8±238.8 | 1020 | 1040.7±203.2 | 302 | 1051.7±228.9 |
| IgA (mg dl⁻¹) | <65 | 68.8±22.2 | <65 | 91.9±37.4 | <65 | 116.7±45.9 | 32.3 | 108.4±42.3 | <65 | 115.8±43.0 |
| IgM (mg dl⁻¹) | 77 | 86.1±35.3 | 853 | 105.8±40.8 | 173 | 93.9±49.3 | 226 | 97.6±42.9 | 769 | 102±43.8 |
| IgE (IU ml⁻¹) | 0.13 | 2–199 | <0.01 | 2–69 | <0.01 | 2–403 |
| C3 (mg dl⁻¹) | 90.5 | 90–180 | 86 | 90–180 | 192 | 90–180 | 93.8 | 90–180 | 109 | 90–180 |
| C4 (mg dl⁻¹) | 7.2 | 10–4 | 6.8 | 10–40 | 38.6 | 10–40 | 6.58 | 10–40 | 19.9 | 10–40 |
| White blood cells (mm⁻³) | 6150 | 985±2772 | 12800 | 985±2772 | 15950 | 726±2424 | 12700 | 726±2424 | 5340 | 726±2424 |
| Absolute lymphocyte count (cells mm⁻³) | 3200 | 455±1517 | 2110 | 455±1517 | 2210 | 277±912 | 1380 | 277±912 | 1120 | 277±912 |
| CD3+ T cells (%) | 87 | 70.0±7.18 | 90 | 70.0±7.18 | 92 | 71.6±51 | 76 | 71.6±51 | 91 | 71.6±51 |
| (mm⁻³) | 2784 | 3220±1180 | 1900 | 3220±1180 | 2033 | 198±709 | 1048 | 198±709 | 1019 | 198±709 |
| CD4+ B cells (%) | 4.4 | 16.5±5.70 | 0.8 | 16.5±5.70 | 0.3 | 13.±5.78 | 21 | 13.±5.78 | 3 | 13.±5.78 |
| (mm⁻³) | 141 | 739±329 | 17 | 739±329 | 7 | 377±202 | 290 | 377±202 | 34 | 377±202 |
| CD3+CD4+ Th cells (%) | 59 | 40.3±7.27 | 57 | 40.3±7.27 | 30 | 40.0±10.1 | 37 | 40.0±10.1 | 20 | 40.0±10.1 |
| (mm⁻³) | 1888 | 1314±542 | 1202 | 1314±542 | 663 | 818±395 | 510 | 818±395 | 224 | 818±395 |
| CD3+CD8+ T cells (%) | 24 | 24.2±5.48 | 31 | 24.2±5.48 | 60 | 25.7±5.58 | 33 | 25.7±5.58 | 65 | 25.7±5.58 |
| (mm⁻³) | 768 | 803±417 | 654 | 803±417 | 1326 | 515±244 | 455 | 515±244 | 728 | 515±244 |
| CD3+CD166+ NK cells (%) | 4 | 11.2±4.85 | 5 | 11.2±4.85 | 5 | 10.6±5.63 | 1.4 | 10.6±5.63 | 3 | 10.6±5.63 |
| (mm⁻³) | 128 | 509±295 | 106 | 509±295 | 110 | 264±61 | 19 | 264±61 | 34 | 264±61 |
| CD3+HLA-DR+ active T cells (%) | 23 | 7.8±4.37 | 25 | 7.8±4.37 | 37 | 8.1±5.0 | 12.4 | 8.1±5.0 | 32 | 8.1±5.0 |
| (mm⁻³) | 736 | 375±235 | 528 | 375±235 | 818 | 241±185 | 171 | 241±185 | 358 | 241±185 |
| CD3+CD4+CD8-TCRαβ+ T cells (%) | 0.39 | 0.7 | 0.7 | 0.7 | Partially reduced | 0.7 | 0.34 | 0.34 | 0.34 | 0.34 |
| CD4+CD25+/Foxp3+ (%) | 1.38 | 0.75 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 |

*T complement 3 (C3) and C4 levels were measured with commercially available nephelometric kits (Siemens).
(Hb: 5 g dl\(^{-1}\), reticulocyte 30 %, direct Coombs ++), hepatosplenomegaly and lymphadenomgalies. He also had proteinuria (10 mg m\(^{-2}\)h\(^{-1}\)) and low C4 level; kidney biopsy revealed focal segmental glomerulosclerosis. He had been followed for ALPS and prescribed low-dose corticosteroids.

On admission, he had normal growth percentiles (weight 50–75 %, height 25 %), tachypnoea, bilateral rhonchi, fine crackles and hepatosplenomegaly (spleen 2–3 cm, liver 5–6 cm below the costal margin). Complete blood count was normal except a mild lymphopenia (Table 2). He had mild hypoalbuminaemia (T protein: 6.3 g dl\(^{-1}\), albumin: 3 g dl\(^{-1}\), high C-reactive protein and erythrocyte sedimentation rate (9.7 mg dl\(^{-1}\), 80 mm h\(^{-1}\), respectively). He had normal IgG, high IgM and low IgA, IgE and C4 levels (Table 2). Lymphocyte subgroups and CD4/CD8-TCR \(\alpha/\beta\) DN T cells were in the normal range (Table 2). Autoantibodies (antinuclear antibody, antithyroid peroxidase, antithyroglobulin antibodies) were negative while direct Coombs test was highly positive. Thyroid hormones were normal. Tuberculin skin test and IFN-\(\gamma\) release assay were negative. He had no proteinuria. Chest X-ray and thorax CT revealed bilateral extensive infiltrations and findings of chronic bronchitis/bronchiolitis.

He had recurrent/non-persistent diarrhoea (enteropathy), recurrent lower respiratory tract infections, chronic lung disease, a mild nephropathy, non-malign lymphoproliferation, autoimmune haemolytic anaemia, hypoalbuminaemia, some immunoglobulin and complement abnormalities, and a brother with severe enteropathy and lymphoproliferation.

With preliminary diagnosis of IPEX syndrome, prophylaxis with antibiotics and antifungals and regular IVIG replacement were started for immune thrombocytopenia. Low-dose corticosteroids (0.3–0.5 mg kg\(^{-1}\) day\(^{-1}\)) was continued for autoimmune cytopaenias.

In his 4-year follow up he had recurrent lower respiratory tract infections and diarrhoea. IgG level declined and IgM level increased progressively. Partial IgA deficiency progressed to complete deficiency and C3/C4 levels normalized over time (Table 2). Subcutaneous immunoglobulin replacement therapy was started. Because he had no matched sibling donor, we began a search for a matched unrelated donor for HSCT. In his 6th month of abatacept treatment, showed better clinical condition, with a short hospitalization for a mild lower respiratory tract infection. Chest X ray showed significant improvement (Fig. 2b).

**DISCUSSION**

The major clinical findings of the first case were chronic diarrhoea (enteropathy), failure to thrive and nephropathy at admission. He had laboratory abnormalities related to enteropathy (iron deficiency anaemia, hypoalbuminaemia) and immunological defects (low IgA, IgE and C4 levels and B cell percentage). *Salmonella* and CMV infections, positive direct Coombs test, and compensatory hypothyroidism
were additional evidence for immune deficiency, autoimmunity and endocrinological involvement, respectively.

During follow-up, Patient 1 developed hepatosplenomegaly, lymphadenomegaly, antithyroid antibody positivity, recurrent pneumonia and granulomatous lung disease. The presence of a brother with autoimmune cytopaenia, lymphoproliferation, recurrent diarrhoea (a milder enteropathy), recurrent respiratory infections, nephropathy and positive direct Coombs test provided evidence of a genetic disease.

The clinical picture of Patient 1 in particular suggested IPEX syndrome. IPEX syndrome is caused by mutations in FOXP3, a key transcription factor for Treg cells, causing dysfunction of Treg cells and autoimmunity affecting numerous organs. Autoimmune enteropathy is the leading finding presenting as forms of diarrhoea, gastritis or colitis [10–12]. Patient 1 had chronic diarrhoea starting in the first year of life, resulted in failure to thrive and gastritis and colitis. Patient 2 had a mild, late-onset enteropathy and pathological evidence of gastritis and colitis.

Autoimmune manifestations in IPEX syndrome are generally early-onset findings but may develop later. Autoimmune endocrinopathies [type 1 diabetes mellitus (50 %), thyroiditis (20 %)] and autoimmune cytopenias [AIHA, thrombocytopenia (ITP) and neutropenia] are frequently seen in IPEX patients [10, 11]. Patient 1 had positive antithyroid antibodies and direct Coombs test without cytopenias. Patient 2 showed autoimmune cytopenias in all three series at different ages and even under immune suppressive treatment.

In IPEX syndrome, renal involvement may be seen as tubulonephropathy, nephrotic syndrome, interstitial nephritis and membranous glomerulonephritis [10, 13]. Both patients had proteinuria and renal disease on their first admission.

After many years of follow-up with a clinical diagnosis of IPEX syndrome, it was found that the FOXP3 gene was not mutated in our patients. The definition IPEX-like disorder had been used for patients having clinical presentations similar to IPEX syndrome, but without mutations in the FOXP3 gene. Loss-of-function mutations in CD25 (IL2RA), STAT5b, ITCH and gain-of-function mutations in STAT1 were found to be responsible for IPEX-like disorders [14, 15].
In IPEX syndrome patients, Treg cells may be in normal numbers with impaired cell function [16, 17]. By contrast, studies investigating Treg cells in IPEX-like disorders revealed different results. Moes et al. found that percentages of FOXP3-expressing Treg cells and their suppressive function were normal or reduced in patients who had early-onset autoimmune enteropathy [18]. In another study with IPEX-like patients, Treg cell numbers were reduced but their suppressive function was preserved [14]. These contrasting outcomes may be due to the fact that there are heterogeneous groups of cases without proven molecular defects. While waiting for molecular studies, we followed our patients with the diagnosis of IPEX-like disorders.

Recently, in a boy with IPEX phenotype, an LRBA mutation, was detected based on whole exom sequencing. Because of similarity with IPEX syndrome, the investigators examined Treg cells of this patient and five other patients with LRBA mutations. CD4+FOXP3+ Treg cells and known cell markers were significantly reduced compared to controls and suppressive function was depressed [19]. Flow cytometric CD4+CD25+FOXP3+ Treg cell percentages were also low in our patients (1.4 and 0.7% in patients 1 and 2, respectively), but functional studies could not be performed.

Hypogammaglobulinaemia with low or normal B cells is a characteristic feature of CVID patients. Autoimmune, auto-inflammatory and lymphoproliferative findings such as enteropathy, GLILD and organomegaly frequently accompany CVID [20]. There are numerous identified genetic defects in CVID phenotype, although some remain to be specified [1]. Many patients having enteropathy and/or GLILD and followed as CVID were finally diagnosed as having CTLA-4 or LRBA deficiency [20], like our patients.

**Fig. 2.** (a) Chest X-ray and thorax CT of Patient 2 (at 10 years of age): bilateral patchy and nodular infiltrations with indistinct margins and coarse septal thickenings. (b) Chest X-ray before and after abatacept therapy (6 months): bilateral hazy parenchymal infiltrations at the start of abatacept therapy. There was almost complete resolution of parenchymal infiltrations with only residual coarse reticular interstitial markings.
Fig. 3. (a) TNGS analysis of the genomic DNA of Patient 1. A nonsense mutation in Exon 21 (c.2496C>A) changes a cystein (C) codon (GCA) into a translation termination (X) codon (TGA) at amino acid position 832 (p.Cys832Ter). (b) Sanger sequencing analysis of the genomic DNA of Patient 1. (c) Pedigree of the family. Affected siblings (V-1 and V-2) are homozygous and both parents (IV-4 and IV-5) are heterozygous for the C832X mutation.
GLILD is frequently seen in patients with LRBA deficiency (38%), which is known as an immune defect affecting Treg cells [5]. Our first patient had a radiological diagnosis of granulomatous lung disease and bronchiectasis, and the second patient had biopsy-proven interstitial lung disease (LIP and follicular bronchiolitis). Immunohistochemical staining of the specimen revealed a high proliferation index (Ki67), presence of CD20+ B cells and CD3+ T cells within lymphoid aggregates consistent with previous data [21]. Immunohistochemical analysis of specimens from CVID patients diagnosed as GLILD showed a predominance of CD4+ T cells or CD20+ B cells and additionally absence of FOXP3+ Treg cells [22], suggesting that Treg cell dysfunction may contribute to the pathology [20].

A recent consensus statement on the management of GLILD in CVID patients reported corticosteroid use as first-line treatment and azathioprine, rituximab and mycophenolate as second-line agents with more than 80% agreement [23]. In Patient 2, development of GLILD could not be prevented despite long-term treatment with corticosteroid and mycophenolate mofetil.

The presence of findings of immune dysregulation (in the form of GLILD, enteropathy, AIHA, ITP, diabetes mellitus, neutropenia, hepatitis, arthritis, etc.) may reach 95% in some cohorts of LRBA-deficient patients. Consequently, corticosteroids and other immunosuppressive or immunomodulatory drugs (such as cyclosporine, mycophenolate mofetil, sirolimus, rituximab, infliximab, rapamycin, hydroxychloroquine, azathioprine and abatacept) are widely used [4–6]. However, most of the reports lack details about response to therapy. In a study including nine patients, three patients with interstitial lung disease were treated with abatacept and showed significant improvement in clinical status, respiratory function and radiological findings. Abatacept, a CTLA-4-immunoglobulin fusion protein, restores the insufficient CTLA-4 function in cells, which is the key point in LRBA deficiency. After the success of that study, they used abatacept in three patients with enteropathy and in a 6-month period two of them showed improvement, one with additional improvement to his uveitis and arthritis [8]. Kostel et al. described seven patients with LRBA mutations. Systemic corticosteroids, cyclosporine and mycophenolate mofetil were partially effective but could not prevent disease progression and emergence of new autoimmune findings. They used abatacept in two patients: one with GLILD responded well; the other with resistant ITP and enteropathy had no response and died due to intracranial haemorrhage [6].

We started abatacept in our patients after identification of LRBA deficiency. Patient 2 showed good respiratory improvement within 6 months. Patient 1 developed fungal oesophagitis and pneumonia in a few days after the first dose of abatacept, leading to interruption of treatment, and responded well to antifungal treatment. Fungal infections probably related to immunosuppressive therapy were reported in LRBA-deficient patients [5, 6]. Two patients under abatacept therapy were reported as acquiring chronic norovirus infection, but this was also defined in CVID and LRBA patients who did not take any medication [8]. Patient 1 responded partially to mycophenolate mofetil in terms of enteropathy and hospital admissions. In the context of a lack of a clear relationship between fungal infection and medication, we decided to start abatacept again.

Given the different outcomes associated with immunosuppressive therapies, HSCT seems to be the only curative treatment in LRBA patients. Eight of 12 patients treated with HSCT survived (67%) as of this writing, most of them with good response [24]. We planned HSCT for our patients long before the genetic diagnosis of LRBA deficiency. Although donors were found recently for both of them, the rejection of HSCT by the family makes immunosuppressive treatment the only option for now.

**CONCLUSION**

Recurrent infections, autoimmunity affecting multiple organ systems, lymphoproliferation and hypogammaglobulinaemias should be important suggestive findings for immune dysregulation syndromes. It should be kept in mind that both similar clinical presentations of different genetic defects and different findings of the same mutation are possible.

Early identification of the disease and early intervention with HSCT may be life saving in LRBA deficiency as with many other immunodeficiency syndromes. Immunosuppressive agents are good treatment options in the period between diagnosis and HSCT.

---

**Funding information**

This work received no specific grant from any funding agency.

**Conflicts of interest**

The authors declare that there are no conflicts of interest.

**Ethical statement**

Written informed consent for publication was obtained from the father of the two patients.

**References**

1. Picard C, Bobby Gaspar H, Al-Hezr W, Bousfiha A, Casanova JL et al. International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol 2018;38:96–128.
2. Lopez-Herrera G, Tampella G, Pan-Hammarström Q, Herholz P, Trujillo-Vargas CM et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet 2012;90:986–1001.
3. Alangari A, Alsultan A, Adly N, Massaad MJ, Kiani IS et al. LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency. J Allergy Clin Immunol 2012;130:481–488.
4. Azizi G, Abolhassani H, Mahdaviani SA, Chavoshzadeh Z, Eshghi P et al. Clinical, immunologic, molecular analyses and outcomes of iranian patients with LRBA deficiency: a longitudinal study. Pediatr Allergy Immunol 2017;28:478–484.
5. Gámez-Díaz L, August D, Stepensky P, Revel-Vilk S, Seidel MG et al. The extended phenotype of LPS-responsive beige-like
anchor protein (LRBA) deficiency. J Allergy Clin Immunol 2016;137: 223–230.
6. Kostel Bal S, Haskologlu S, Serwas NK, Islamoglu C, Aytekin C et al. Multiple presentations of lrba deficiency: a single-center experience. J Clin Immunol 2017;37:790–800.
7. Sansom DM. IMMUNOLOGY. Moving CTLA-4 from the trash to recycling. Science 2015;349:377–378.
8. Lo B, Zhang K, Lu W, Zheng L, Zhang Q et al. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 2015;349:436–440.
9. Lo B, Abdel-Motal UM. Lessons from CTLA-4 deficiency and checkpoint inhibition. Curr Opin Immunol 2017;49:14–19.
10. Barzaghi F, Passerini L, Bacchetta R. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front Immunol 2012;3:211.
11. Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C et al.JM2, encoding a fork head-related protein, is mutated in X-linked autoimmune-allergic deregulation syndrome. J Clin Invest 2000;106:R75–R81.
12. Zama D, Cocchi I, Masetti R, Specchia F, Alvisi P et al. Late-onset of immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) with intractable diarrhea. Ital J Pediatr 2014;40:68.
13. Sheikine Y, Woda CB, Lee PY, Chatila TA, Keles S et al. Renal involvement in the immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) disorder. Pediatr Nephrol 2015;30:1197–1202.
14. Barzaghi F, Passerini L, Gambineri E, Giullini Mannurita S, Cornu T et al. Demethylation analysis of the FOXP3 locus shows quantitative defects of regulatory T cells in IPEX-like syndrome. J Autoimmun 2012;38:49–58.
15. Verbsky JW, Chatila TA. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases. Curr Opin Pediatr 2013;25:708–714.
16. Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006;116:1713–1722.
17. D’Hennezel E, Ben-Shoshan M, Ochs HD, Torgerson TR, Russell LJ et al. FOXP3 forkhead domain mutation and regulatory T cells in the IPEX syndrome. N Engl J Med 2009;361:1710–1713.
18. Moes N, Rieux-Laucat F, Begue B, Verdier J, Neven B et al. Reduced expression of FOXP3 and regulatory T-cell function in severe forms of early-onset autoimmune enteropathy. Gastroenterology 2010;139:770–778.
19. Charbonnier LM, Janssen E, Chou J, Ohsumi TK, Keles S et al. Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. J Allergy Clin Immunol 2015;135:217–227.
20. Safi M, Wysocki CA. Autoimmune disease in primary immunodeficiency: at the crossroads of anti-infective immunity and self-tolerance. Immunol Allergy Clin North Am 2015;35:731–752.
21. Park JH, Levinson AI. Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Curr Opin Immunol 2010;23:97–103.
22. Rao N, Mackinnon AC, Routes JM. Granulomatous and lymphocytic interstitial lung disease: a spectrum of pulmonary histopathologic lesions in common variable immunodeficiency-histologic and immunohistochemical analyses of 16 cases. Hum Pathol 2015;46:1306–1314.
23. Hurst JR, Verma N, Lowe D, Baxendale HE, Jolles S et al. British lung foundation/united kingdom primary immunodeficiency network consensus statement on the definition, diagnosis, and management of granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency disorders. J Allergy Clin Immunol Pract 2017;5:938–945.
24. Seidel MG, Böhkm, Dogu F, Worth A, Thraisher A et al. Treatment of severe forms of LPS-responsive beige-like anchor protein deficiency with allogeneic hematopoietic stem cell transplantation. J Allergy Clin Immunol 2018;141:770–775.
25. Aksu G, Genel F, Koturoğlu G, Kurugöl Z, Kütükçüler N. Serum immunoglobulin (IgG, IgM, IgA) and IgG subclass concentrations in healthy children: a study using nephelometric technique. Turk J Pediatr 2006;48:19–24.
26. Azarsiz E, Karaca NE, Aksu G, Kutukçüler N. Reference values for B-cell surface markers and co-receptors associated with primary immune deficiencies in healthy Turkish children. Int J Immunopathol Pharmacol 2017;30:194–200.
27. Martins TB, Bandhauer ME, Bunker AM, Roberts WL, Hill HR. New childhood and adult reference intervals for total IgE. J Allergy Clin Immunol 2014;133:589–591.